Key Takeaways Ultragenyx Pharmaceutical (RARE) reported first-quarter 2026 loss of $1.84 per share, wider than the Zacks Consensus Estimate of a loss of $1.55. The company had incurred a loss of $1.57 per share in the year-ago quarter. Ultragenyx's total revenues amounted to $136 million in the reported quarter, which declined 2% year over year due to lower product sales. The top line missed the Zacks Consensus Estimate of $161 million. The company markets four drugs, namely Crysvita, Mepsevii, Dojolvi and ...

核心财务表现摘要 - 2026年第一季度营收为1.36亿美元，同比下降2.4%，远低于市场预期的1.6126亿美元，营收未达预期幅度为-15.66% [1] - 第一季度每股收益为-1.84美元，低于去年同期的-1.57美元，且未达到市场预期的-1.55美元，每股收益未达预期幅度为-18.96% [1] 分产品线收入分析 - **Dojolvi**：收入为1800万美元，同比增长5.8%，但低于六位分析师的平均预期2067万美元 [4] - **Evkeeza**：收入为1800万美元，同比大幅增长63.2%，且超过六位分析师1622万美元的平均预期 [4] - **Mepsevii**：收入为700万美元，同比下降16.5%，且低于六位分析师937万美元的平均预期 [4] - **Crysvita总收入**：为9300万美元，远低于五位分析师1.1417亿美元的平均预期 [4] 收入构成与市场表现 - **产品销售收入**：为8900万美元，同比下降2.7%，且低于四位分析师9498万美元的平均预期 [4] - **特许权使用费收入**：为4700万美元，低于四位分析师6278万美元的平均预期 [4] - 过去一个月公司股价回报率为+8.5%，略低于标普500指数+9.5%的涨幅 [3]

First quarter total revenue of $136 million, Crysvita® revenue of $93 million and Dojolvi® revenue of $18 million Reaffirm 2026 financial guidance, including total revenue of $730 million to $760 million and combined R&D and SG&A expenses to be flat to slightly down versus 2025; remain on path to profitability in 2027 GTX-102 for Angelman syndrome: New longer-term data from Phase 1/2 clinical study support durable and improving effects across multiple domains; Phase 3 data expected in the second half of 20 ...